Amgen | AMGN

Stock Price
283.64
Daily Change
3.54 1.26%
Monthly
-0.36%
Yearly
-11.49%
Q3 Forecast
281.29

Peers Price Chg Day Year Date
Takeda 4,574.00 33.00 0.73% 7.09% Sep/05
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Agios Pharmaceuticals 36.01 -0.12 -0.33% -16.80% Sep/05
ALKERMES 29.94 1.02 3.53% 11.47% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Exelixis 37.88 0.50 1.34% 50.62% Sep/05
Genmab 1,751.50 6.50 0.37% -5.83% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Novartis 129.82 1.34 1.04% 11.22% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Teva Pharmaceutical Industries 6,275.00 -65.00 -1.03% -9.12% Sep/04
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05

Indexes Price Day Year Date
US500 6481 -20.59 -0.32% 19.84% Sep/05
USND 21700 -7.31 -0.03% 30.01% Sep/05
US30 45401 -220.43 -0.48% 12.53% Sep/05
US100 23652 19.43 0.08% 28.40% Sep/05

Amgen traded at $283.64 this Friday September 5th, increasing $3.54 or 1.26 percent since the previous trading session. Looking back, over the last four weeks, Amgen gained 0.36 percent. Over the last 12 months, its price fell by 11.49 percent. Looking ahead, we forecast Amgen to be priced at 281.29 by the end of this quarter and at 274.34 in one year, according to Trading Economics global macro models projections and analysts expectations.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.